IP Library Patent Application 13605629
Patent Application
App. No. 13/605,629

IL-17 Heteromeric Receptor Complex

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/605,629
Abstract

The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active.

Claims (18)

1 - 72 . (canceled)

73 . A method of screening candidate agents for IL-17RA-IL-17RC antagonists, comprising:

a) exposing a candidate agent to a cell expressing IL-17RA, IL-17RC, and IL-17RA-IL-17RC heteromeric receptor complex;

b) measuring IL-17RA-IL-17RC heteromeric receptor complex formation in said cell; and

c) selecting a subset of said candidate agents that inhibit IL-17RA-IL-17RC heteromeric receptor complex formation.

74 . A method of screening candidate agents for IL-17RA-IL-17RC antagonists, comprising:

a) providing an IL-17RA, IL-17RC, and a IL-17RA-IL-17RC heteromeric receptor complex;

b) exposing a candidate agent to said IL-17RA, IL-17RC, and a IL-17RA-IL-17RC heteromeric receptor complex of step a);

c) determining the amount of receptor complex formation relative to not having been exposed to said candidate agent; and

d) selecting a subset of said candidate agents that inhibit IL-17RA-IL-17RC heteromeric receptor complex formation.

75 . A method of screening candidate agents that inhibit IL-17RA-IL-17RC heteromeric receptor complex activation, comprising:

a) providing a cell expressing IL-17RA, IL-17RC, and a IL-17RA-IL-17RC heteromeric receptor complex;

b) exposing a candidate agent to said cell of step a);

c) exposing said cell of step a) and the candidate agent of step b) to an IL-17 ligand family member;

c) determining the amount of IL-17RA-IL-17RC heteromeric receptor complex activation relative to not having been exposed to said candidate agent; and

d) selecting a subset of said candidate agents that inhibit IL-17RA-IL-17RC heteromeric receptor complex activation.

76 . The method of claim 75 , wherein the IL-17 ligand is IL-17A, IL-17F, or both IL-17A and IL-17F.

77 . The method of claim 75 , wherein step c) comprises measuring at least one of the following IL-6, IL-8, CXCL1, CXCL2, GM-CSF, G-CSF, M-CSF, IL-1β, TNFα, RANK-L, LIF, PGE2, iL-12, MMP3, MMP9, GROα, NO.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2013
From: AMGEN INC.
To: KIRIN-AMGEN, INC.
Reel/Frame 030045/0876 →